The estimated Net Worth of Chids Mahadevan is at least $52.6 Thousand dollars as of 16 May 2022. Mr Mahadevan owns over 905 units of Applied Therapeutics stock worth over $51,058 and over the last 3 years he sold APLT stock worth over $1,493.
Mr has made over 1 trades of the Applied Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 905 units of APLT stock worth $1,493 on 16 May 2022.
The largest trade he's ever made was selling 905 units of Applied Therapeutics stock on 16 May 2022 worth over $1,493. On average, Mr trades about 226 units every 0 days since 2021. As of 16 May 2022 he still owns at least 9,800 units of Applied Therapeutics stock.
You can see the complete history of Mr Mahadevan stock trades at the bottom of the page.
Chids Mahadevan is the VP of Fin. & Chief Accounting Officer at Applied Therapeutics.
Mr Mahadevan is 52, he's been the VP of Fin. & Chief Accounting Officer of Applied Therapeutics since . There are 6 older and 5 younger executives at Applied Therapeutics. The oldest executive at Applied Therapeutics, Inc. is Jay Skyler, 73, who is the Independent Director.
Chids's mailing address filed with the SEC is C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017.
Over the last 5 years, insiders at Applied Therapeutics have traded over $14,309,660 worth of Applied Therapeutics stock and bought 5,072,897 units worth $17,896,654 . The most active insiders traders include Real Estate Equities, Inc.A..., Joel S Marcus, and Shoshana Shendelman. On average, Applied Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $573,736. The most recent stock trade was executed by Leslie D. Funtleyder on 22 August 2024, trading 13,530 units of APLT stock currently worth $78,880.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Applied Therapeutics executives and other stock owners filed with the SEC include: